Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by mumfordsenon Jun 23, 2018 12:32am
117 Views
Post# 28217485

RE:RE:Here's Why This Is Such a Great Buy Right NOW!!!

RE:RE:Here's Why This Is Such a Great Buy Right NOW!!!
Hotoffthepress wrote: So as far as I'm concerned we have at least 4 pieces of MAJOR NEWS between now and mid August. This does not include Partnership anouncements or outlicensing of Bertilimumab in Ocular indications which I understand hey are persuing.  We may be looking at 5-6 PR's in the short term.  There's NO WAY we will be under 20 cents, maybe 30, 40 or even 50 cents.  Trust me, this is a STRONG BUY under a Dime.  Buy, hold, prosper ....


You sold at 15/16 cents?
<< Previous
Bullboard Posts
Next >>